文献速递青光眼

苯扎氯铵防腐剂滴眼液与其他防腐剂及无防腐剂滴眼液治疗青光眼的疗效与安全性:系统综述与荟萃分析

Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
PubMed 文献 · Br J Ophthalmol · 2020-02-12

该系统综述与荟萃分析比较了苯扎氯铵(BAK)防腐滴眼液与其他防腐剂(AP)及无防腐剂(PF)滴眼液在青光眼或高眼压患者中的疗效与安全性。纳入16项随机对照试验,其中13项(4201例患者)纳入眼压荟萃分析,随访15天至6个月。结果显示BAK与AP及PF在眼压变化、结膜充血、眼部充血、总眼部不良事件或泪膜破裂时间方面均无显著差异,但安全性存在较大不确定性。

要点

  • BAK与AP及PF滴眼液在眼压变化上无显著差异(95%CI -0.00至0.30 mmHg,p=0.05)。
  • 结膜充血、眼部充血、总眼部不良事件及泪膜破裂时间在组间均无显著差异。
  • 安全性指标报告异质性大,多数领域偏倚风险高或不明确,安全性结论不确定。

核心结论

  • BAK与AP及PF滴眼液在疗效或安全性上未确定有临床显著差异,但安全性存在较大不确定性。

研究设计与样本

  • 纳入使用前列腺素类似物或β受体阻滞剂滴眼液且诊断为青光眼或高眼压的患者。
  • 眼压荟萃分析纳入13项研究共4201例患者,随访时间15天至6个月。

主要发现

  • BAK与PF及AP在眼压变化上无显著差异(95%CI -0.00至0.30 mmHg,p=0.05)。
  • 结膜充血风险比1.05(95%CI 0.91至1.22,3800例患者,9项研究)。
  • 眼部充血风险比1.31(95%CI 0.96至1.78,2268例患者,5项研究)。
  • 总眼部不良事件风险比1.03(95%CI 0.88至1.20,1906例患者,5项研究)。
  • 泪膜破裂时间均数差0.89(95%CI -0.03至1.81,130例患者,3项研究)。

关键数值与推荐

  • 主要结局为眼压变化,次要结局为原始研究评估的安全性指标。
  • 安全性指标报告多样导致比较困难,许多相关领域偏倚风险高或不明确。

临床怎么用

  • 在青光眼或高眼压患者中,BAK防腐滴眼液与其他防腐剂或无防腐剂滴眼液在眼压控制上未见显著差异。
  • 选择滴眼液时需考虑安全性证据的不确定性,尤其对眼表健康关注的患者。

局限性

  • 安全性指标报告异质性大,比较困难。
  • 许多相关领域偏倚风险高或不明确,提示潜在的选择性报告或报告不足。
  • 安全性存在较大不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: This systematic review compared the efficacy and safety of benzalkonium chloride (BAK)-preserved eye-drops with alternatively preserved (AP) and preservative-free (PF) eye-drops. METHODS: PubMed, EMBASE and MEDLINE were searched for randomised controlled trials in June and October 2019. Study selection, data extraction and risk of bias assessment were made by two independent reviewers using the Cochrane Handbook. Studies on prostaglandin analogue or beta-blocker eye-drops and patients with glaucoma or ocular hypertension were included. Primary outcome was change in intraocular pressure (IOP). Secondary outcomes were safety measures as assessed in original study. RESULTS: Of 433 articles screened, 16 studies were included. IOP meta-analysis was conducted on 13 studies (4201 patients) ranging from 15 days to 6 months. No significant differences between BAK versus PF and AP were identified (95% CI -0.00 to 0.30 mm Hg, p=0.05). Meta-analyses revealed no differences between BAK versus AP and PF with regards to conjunctival hyperaemia (risk ratio (RR) 1.05, 95% CI 0.91 to 1.22, 3800 patients, 9 studies), ocular hyperaemia (RR 1.31, 95% CI 0.96 to 1.78, 2268 patients, 5 studies), total ocular adverse events (RR 1.03, 95% CI 0.88 to 1.20, 1906 patients, 5 studies) or tear break-up time (mean difference 0.89, 95% CI -0.03 to 1.81, 130 patients, 3 studies). Diverse reporting on safety measures made comparison challenging. Risk of bias was assessed as high or unclear in many relevant domains, suggesting potential selective reporting or under-reporting. CONCLUSION: No clinically significant differences on efficacy or safety could be determined between BAK versus AP and PF. However, there were substantial uncertainties on safety.PROSPERO registration numberCRD42019139692.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hedengran A, Steensberg AT, Virgili G, et al. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol. 2020. PMID: 32051133. doi:10.1136/bjophthalmol-2019-315623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。